Modality
Small Molecule
MOA
BTKi
Target
FXIa
Pathway
T-cell
ASRB
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
~Nov 2019
→ ~Feb 2021
Phase 2
May 2021
→ Jun 2031
Phase 2Current
NCT03753787
1,365 pts·AS
2021-05→2031-06·Not yet recruiting
1,365 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-105.2y awayPh2 Data· AS
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Not yet…
Catalysts
Ph2 Data
2031-06-10 · 5.2y away
AS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03753787 | Phase 2 | AS | Not yet recr... | 1365 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 |